Purple Biotech Advances Tri-Specific Antibody IM1240, Paving Way for Tumor-Targeted Immunotherapy Trials
IM1240 Manufacturing Breakthrough Positions CAPTN-3 Platform for Clinical Milestone
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) achieved a significant milestone in the development of IM1240, its tri-specific antibody, by reaching a commercially viable yield through its proprietary CAPTN-3 platform. This step validates both the platform’s scalability and its competitiveness in the rapidly evolving field of immune-oncology, as the company targets a first-in-human clinical trial with an IND submission slated for 2026.
Innovative Mechanism of Action and Enhanced Safety Profile Stand Out
IM1240 is designed to activate both T cells and natural killer (NK) cells, utilizing a three-pronged targeting approach. By engaging the tumor-associated antigen 5T4, activating CD3 on T cells, and blocking the inhibitory NKG2A on NK and CD8+ T cells, IM1240 orchestrates a potent immune response aimed at solid tumors that often evade standard therapies. Notably, its cleavable, albumin-bound cap confines immune activation to the tumor microenvironment, potentially reducing systemic side effects—a common challenge in cancer immunotherapy.
| Key IM1240 Features | Details |
|---|---|
| Target Antigen | 5T4 (associated with advanced, invasive tumors) |
| Dual Cell Engagement | T cells (CD3) & NK/CD8+ T cells (NKG2A) |
| Manufacturing Milestone | High yield & purity validated |
| Safety Feature | Cleavable albumin-bound cap for local immune activation |
| Next Steps | IND filing planned for 2026; first-in-human clinical trial |
Platform Potential: Multiple Pipeline Programs and Broader Cancer Applications
IM1240 represents the lead asset in Purple Biotech’s CAPTN-3 platform, which focuses on conditionally activated tri-specific antibodies with a broad capacity to tackle various tumor types. The company’s broader pipeline includes a second tri-specific antibody (IM1305, targeting TROP2) and additional assets in combination immunotherapies and targeted small molecules, highlighting a diversified approach to overcoming tumor resistance and immune evasion.
Key Takeaway: PPBT's Strategic Progress Highlights Potential for Clinical Impact
Purple Biotech’s successful scale-up of IM1240 places the company in a competitive position to deliver on the promise of tri-specific antibody therapies that may address the pressing challenge of solid tumor resistance. As the company prepares for regulatory filings and initial human studies, this manufacturing and development achievement signals a notable stride in next-generation immuno-oncology approaches. For investors and biotech watchers, Purple Biotech’s evolution is worth monitoring as it moves closer to unlocking a new class of tumor-targeted therapies.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI